Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2026)

Sarepta Therapeutics has reported Tax Provisions for 10 years, with the latest figure at $3.1 million in Q2 2026.

• On a quarterly basis, Tax Provisions rose 107.25% year-over-year to $3.1 million in Q2 2026; TTM through Jun 2026 was $6.2 million, a 81.88% decrease from a year earlier, with the FY2025 full-year figure at $11.5 million, down 55.21% from the prior year.
• Tax Provisions was $3.1 million for Q2 2026 at Sarepta Therapeutics, down from $12.2 million in the prior quarter.
• The five-year high for Tax Provisions was $64.0 million in Q1 2025, with the low at -$43.3 million in Q2 2025.
• Average Tax Provisions over 5 years is $4.6 million, with a median of $4.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Tax Provisions jumped 9193.48% in 2022, then plunged 3625.5% in 2025.
• Over 5 years, Tax Provisions stood at $8.5 million in 2022, then sank by 160.3% to -$5.2 million in 2023, then surged by 351.03% to $12.9 million in 2024, then tumbled by 62.03% to $4.9 million in 2025, then tumbled by 36.08% to $3.1 million in 2026.
• The last three Tax Provisions figures came in at $3.1 million (Q2 2026), $12.2 million (Q1 2026), and $4.9 million (Q4 2025), per Business Quant data.